Metraipolis › archive › dc_48cd5b6d679d

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis — Europe PMC PMID:41806161

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41806161
DOI
10.1002/acn3.70357
License (as archived)
solo-consultazione
Archived
2026-11-04T21:44:10.103Z
SHA-256 of the archived text
3f28f0d19ca377368bc3a7176cd2354c990327371a63f769afd015255aa63692
Stable URL of this page
https://metraipolis.com/documento/dc_48cd5b6d679d

How to cite

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis — Europe PMC PMID:41806161 — Europe PMC (en), https://europepmc.org/article/MED/41806161 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_48cd5b6d679d (Metraipolis archive dc_48cd5b6d679d, sha256 3f28f0d19ca377368bc3a7176cd2354c990327371a63f769afd015255aa63692)
BibTeX
@misc{dc48cd5b6d679d,
  title = {Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis — Europe PMC PMID:41806161},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41806161},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_48cd5b6d679d; sha256 3f28f0d19ca377368bc3a7176cd2354c990327371a63f769afd015255aa63692},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41806161. Agents can read the archived copy with the MCP tool read_document.